Trial Search Results

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

NewLink Genetics Corporation

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Receipt of at least one dose of algenpantucel-L within the past 15 years

   - Signed consent

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Gino Pineda
650-725-8474
Not Recruiting